Andrew Retter - 01 Jun 2025 Form 4 Insider Report for VOLITIONRX LTD (VNRX)

Role: Chief Medical Officer
Signature: /s/ Andrew Retter
Issuer symbol: VNRX
Transactions as of: 01 Jun 2025
Transactions value $: -$2,313
Form type: 4
Filing time: 03 Jun 2025, 16:05:46 UTC
Previous filing: 05 May 2025
Next filing: 03 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Retter Andrew	Chief Medical Officer	1489 WEST WARM SPRINGS ROAD,, SUITE 110, HENDERSON	/s/ Andrew Retter	03 Jun 2025	0002015252

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VNRX	Common Stock	Award	$0	+13.1K	+9.77%	$0.00	147K	01 Jun 2025	Direct	F1
transaction	VNRX	Common Stock	Tax liability	-$2.31K	-4.6K	-3.13%	$0.50	142K	01 Jun 2025	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On June 1, 2025, the reporting person was awarded 13,069 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 4,357 units, 4,356 units, and 4,356 units on each of June 1, 2025, July 1, 2025 and August 1, 2025, respectively, are also subject to further time-based vesting in a single installment on August 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.
F2	Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 9,784 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

Content

On June 1, 2025, the reporting person was awarded 13,069 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 4,357 units, 4,356 units, and 4,356 units on each of June 1, 2025, July 1, 2025 and August 1, 2025, respectively, are also subject to further time-based vesting in a single installment on August 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 9,784 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.